SCM
TRIL

Silverarc Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Silverarc Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-95,190
Closed -$923 – 116
2021
Q2 		$923 Buy
95,190
+35,190
+59% +$331K 0.41% 66
2021
Q1 		$644K Sell
60,000
-50,000
-45% -$618K 0.35% 64
2020
Q4 		$1.62M Buy
+110,000
New +$1.59M 0.94% 38

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Silverarc Capital Management's TRIL Position: Q3 2021 in Review

Silverarc Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 95,190 shares — an estimated $923 sold.

Silverarc Capital Management first reported a position in TRIL in Q4 2020 and held it in 3 quarters. The position peaked at $1.62M in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Silverarc Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 95,190 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $923.
  • Silverarc Capital Management first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 3 quarters.
  • Silverarc Capital Management's Trillium Therapeutics Inc. position peaked at $1.62M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.